Table 2: Flow cytometric quantification of circulating MPs levels among the 107 study patients.

VariablesOne-year survivors 
( )
One-year nonsurvivors 
( )
value

CD31+CD42bAN-V+ (counts/mL)*9604.47 ± 10879.558979.27 ± 8496.780.743
CD31+CD42bAN-V (counts/mL)*942.33 ± 1556.862473.18 ± 3827.600.006
CD31+CD42b+AN-V+ (counts/mL)*30435.52 ± 29380.6239718.43 ± 32105.380.118
CD31+CD42b+AN-V (counts/mL)*92391.74 ± 206545.5848540.96 ± 100731.500.171
CEA45.59 ± 119.28130.11 ± 456.110.177

CD31+CD42bAN-V+ = endothelial-derived apoptotic microparticles; CD31+CD42bAN-V = endothelial-derived activated microparticles; CD31+CD42b+AN-V+ = platelet-derived apoptotic microparticles; CD31+CD42b+AN-V = platelet-derived activated microparticles.
CEA: carcinoembryonic antigen.